SecBot SecBot
8-K ·Filed Apr 23, 2026

FOLD

AMICUS THERAPEUTICS, INC.
NEUTRAL
Impact 6/10
Horizondays Processed6mo ago SEC0001140361-26-016371
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Traders should monitor for the official closing announcement on or around April 27, 2026, which will confirm the delisting of FOLD shares and completion of the acquisition. Arbitrage opportunities may narrow as the closing date approaches.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+5
Entry
$14.49
T+0 close · Apr 23, 2026 · via day close
Latest settled
0.00%
T+5 · $14.49
Vs SPY
−0.91%
α at T+5
Next horizon
T+20
due 6mo ago
  1. T+0 · Apr 24 $14.49entry
  2. T+1 · 7mo ago 0.00%α −0.16% · $14.49
  3. T+5 · 7mo ago 0.00%α −0.91% · $14.49
  4. T+20 · due 6mo ago Pending
  5. T+60 · due 4mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Amicus Therapeutics announced that the French Ministry of Economics and Finance has granted foreign direct investment clearance for its acquisition by BioMarin Pharmaceutical. This satisfies the final regulatory condition, with the merger now expected to close on April 27, 2026.

Key Facts

  • French Ministry of Economics and Finance granted foreign direct investment (FDI) clearance for the merger with BioMarin.
  • This clearance satisfies the final regulatory condition to the merger.
  • The merger is expected to close on April 27, 2026.
  • The transaction was first announced on December 19, 2025.

Financial Impact

The merger will result in Amicus shareholders receiving the agreed-upon consideration per share as specified in the merger agreement, though specific terms are not disclosed in this filing.

share priceownership structuremarket capitalization

Risk Factors

  • Closing is still subject to customary conditions that are to be satisfied at closing, which could delay or prevent completion.
  • Regulatory or legal challenges in other jurisdictions could still emerge despite French FDI approval.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-016371
Document: 0001140361-26-016371-index-headers.html0001140361-26-016371
Document: 0001140361-26-016371-index.html0001140361-26-016371
Document: 0001140361-26-016371.txt0001140361-26-016371

Track record

3 reports on FOLD

Performance horizon
Filters
  1. May 7, 202627w ago 15-12G Neutral 4/10 No price data
  2. Apr 27, 202629w ago 8-K Neutral 9/10 Entry $14.49 No price data
  3. Apr 23, 202629w ago 8-K Neutral 6/10 Viewing Entry $14.49 No price data
Showing 3 of 3

US Market Status

Market Closed · Opens Wed (11h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026